Merck, known as MSD outside of the United States and Canada, and Kelun-Biotech (a holding subsidiary of Sichuan Kelun Pharmaceutical Co., Ltd), a clinical-stage biotech company focused on biologic and small molecule discovery and development, announced that the companies have entered into an exclusive license and collaboration agreement to develop seven investigational preclinical antibody-drug conjugates (ADC) for the treatment of cancer. Read more.
Pages
- B24
- Careers
- Certification of products subject to the requirements of the Consumer Product Safety Improvement Act of 2008 (CPSIA)
- Contact us
- Copyright
- Forward-looking statement
- ical
- Merck | Home
- Products list
- Responsible Vulnerability Disclosure Program of Merck & Co., Inc., Rahway, NJ, USA
- Sitemap
- Stories
- Terms of use
- What we do
- Who we are
- History
- Sustainability
- Environmental sustainability
- Impact Venture Fund
- Merck Medical Outreach Program
- Philanthropy
- Advancing equity in cancer care
- Advancing patient-centered cancer care
- Advancing patient-centered cancer care in resource-limited communities
- Enhancing diabetes care through community outreach and support
- Expanding access to cancer care in Asia
- Global emergency response
- Improving access to high-quality diabetes care
- Improving access to HIV care in sub-Saharan Africa
- Improving health care access
- Merck Foundation
- Merck Richard T. Clark Fellowship for Global Health
- Patient assistance and product donation programs
- Promoting equity in HIV/AIDS care
- Strengthening health systems’ resilience through immunization
- Strengthening our communities
- Sustainability resources
- Transparency disclosures
- Leadership
- Culture & values
- Diversity & inclusion
- Policies & positions
- Business development & licensing
- Suppliers
- Research
- Business development and licensing (BD&L)
- CHLOR-TRIMETON
- Immunology
- Meet our scientists
- Neuroscience
- Postdoctoral research fellows program
- Publications
- Scientific capabilities
- Vaccines
- COVID-19
- Infectious diseases
- Oncology
- Cardio-metabolic diseases
- Pipeline
- Discovery & development
- Clinical trials
- Diversity in clinical trials
- R&D locations
- Patients
- Investor relations
- Media
Archives
Categories
- No categories